Last reviewed · How we verify
NCT04283019
The Pharmacokinetic and Pharmacodynamic Effects of Oral Cannabidiol (CBD) Under Acute and Chronic Exposure Conditions
Phase 1 trial testing CBD in Cannabis, Drug Effects in 75 participants. Completed in 17 June 2024.
17 June 2024
Quick facts
| Lead sponsor | Johns Hopkins University |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 75 |
| Start date | 15 August 2021 |
| Primary completion | 17 June 2024 |
| Estimated completion | 17 June 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
Conditions studied
- Cannabis, Drug Effects — all drugs for Cannabis, Drug Effects →
Sponsor
Johns Hopkins University
Who can join
Adults 18 to 55, any sex, with Cannabis, Drug Effects. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate the pharmacokinetic and pharmacodynamic effects of oral Cannabidiol (with or without low levels of THC), under acute and chronic dosing conditions.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The acute and chronic pharmacokinetics and pharmacodynamics of oral cannabidiol with and without low doses of delta-9-tetrahydrocannabinol.
Wolinsky D, Zamarripa CA, Spindle TR, Klausner M, et al · · 2026 · cited 1× · PMID 40704705 · DOI 10.1093/jat/bkaf075
Verify or expand the search:
- PubMed search for NCT04283019
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CBD
Trials testing the same drug.
- NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
- NCT06878417 — Cannabinoids for Osteoarthritis Pain Effectiveness Trial · NA · recruiting
- NCT06014424 — Cannabidiol Medication Intervention Trial · Phase 2 · recruiting
- NCT05514899 — Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV · Phase 2 · recruiting
- NCT05317013 — CBD in Postmenopausal Women With Osteopenia · Phase 1 · terminated
Other recruiting trials for Cannabis, Drug Effects
Currently open trials in the same condition.
- NCT07176208 — Clinical Study to Evaluate the Effects of Oral Delta-9-tetrahydrocannabinol (Δ9-THC) With and Without Alcohol on Percept · Phase 1 · recruiting
Other Johns Hopkins University trials
Trials by the same sponsor.
- NCT06236542 — Tracheostomy Robotics and Cutting-edge Health Education for Airway Safety · NA · not yet recruiting
- NCT07532252 — Daridorexant for Alcohol Use Disorder · Phase 2 · not yet recruiting
- NCT06687655 — Impact of Exogenous Ketones on Sleep Apnea · Phase 1, PHASE2 · not yet recruiting
- NCT07079111 — 3D Printed Occlusal Splints for Intraoperative Use · NA · not yet recruiting
- NCT02998502 — The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04283019 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Johns Hopkins University
- Last refreshed: 7 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04283019.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing